Cargando…
Author Correction: Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701236/ https://www.ncbi.nlm.nih.gov/pubmed/29176726 http://dx.doi.org/10.1038/s41598-017-16510-2 |
| _version_ | 1783281299729940480 |
|---|---|
| author | Zhao, Ming Chen, Jiayi Yuan, Yanyan Zou, Zuquan Lai, Xiaolong Rahmani, Daud M Wang, Fuyan Xi, Yang Huang, Qin Bu, Shizhong |
| author_facet | Zhao, Ming Chen, Jiayi Yuan, Yanyan Zou, Zuquan Lai, Xiaolong Rahmani, Daud M Wang, Fuyan Xi, Yang Huang, Qin Bu, Shizhong |
| author_sort | Zhao, Ming |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5701236 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-57012362017-11-30 Author Correction: Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials Zhao, Ming Chen, Jiayi Yuan, Yanyan Zou, Zuquan Lai, Xiaolong Rahmani, Daud M Wang, Fuyan Xi, Yang Huang, Qin Bu, Shizhong Sci Rep Author Correction Nature Publishing Group UK 2017-11-24 /pmc/articles/PMC5701236/ /pubmed/29176726 http://dx.doi.org/10.1038/s41598-017-16510-2 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Author Correction Zhao, Ming Chen, Jiayi Yuan, Yanyan Zou, Zuquan Lai, Xiaolong Rahmani, Daud M Wang, Fuyan Xi, Yang Huang, Qin Bu, Shizhong Author Correction: Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials |
| title | Author Correction: Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials |
| title_full | Author Correction: Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials |
| title_fullStr | Author Correction: Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials |
| title_full_unstemmed | Author Correction: Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials |
| title_short | Author Correction: Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials |
| title_sort | author correction: dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials |
| topic | Author Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701236/ https://www.ncbi.nlm.nih.gov/pubmed/29176726 http://dx.doi.org/10.1038/s41598-017-16510-2 |
| work_keys_str_mv | AT zhaoming authorcorrectiondipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials AT chenjiayi authorcorrectiondipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials AT yuanyanyan authorcorrectiondipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials AT zouzuquan authorcorrectiondipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials AT laixiaolong authorcorrectiondipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials AT rahmanidaudm authorcorrectiondipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials AT wangfuyan authorcorrectiondipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials AT xiyang authorcorrectiondipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials AT huangqin authorcorrectiondipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials AT bushizhong authorcorrectiondipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials |